MRKR MARKER THERAPEUTICS INC Other Situations 8-K Filing 2023 - Press Release Marker Therapeutics, Inc. issued a press release reporting pre-clinical data on their T cell product candidate MT-601 in lymphoma cells.Get access to all SEC 8-K filings of the MARKER THERAPEUTICS INC